1
|
Rana S, Ughade S, Kumthekar R, Bhambure R. Chromatography assisted in-vitro refolding and purification of recombinant peptibody: Recombinant Romiplostim a case study. Int J Biol Macromol 2023; 249:126037. [PMID: 37516226 DOI: 10.1016/j.ijbiomac.2023.126037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Revised: 07/16/2023] [Accepted: 07/26/2023] [Indexed: 07/31/2023]
Abstract
In-vitro protein refolding is one of the key rate-limiting unit operations in manufacturing of fusion proteins such as peptibodies expressed using E. coli. Dilution-assisted refolding is the most commonly used industrial practice to achieve the soluble, native functional form of the recombinant protein from the inclusion bodies. This study is focused on developing a chromatography-assisted in-vitro refolding platform to produce the biologically active, native form of recombinant peptibody. Recombinant Romiplostim was selected as a model protein for the study. A plug flow tubular reactor was connected in series with capture step affinity chromatography to achieve simultaneous in-vitro refolding and capture step purification of recombinant Romiplostim. Effect of various critical process parameters like fold dilution, temperature, residence time, and Cysteine: DTT ratio was studied using a central composite based design of experiment strategy to achieve a maximum refolding yield of selected peptibody. Under optimum refolding conditions, the maximum refolding yield of 57.0 ± 1.5 % and a purity of over 79.73 ± 3.4 % were achieved at 25-fold dilution, 15 °C temperature, 6 h residence time with 6 mM and 10 mM of cysteine and DTT, respectively. The formation of native peptibody structure was examined using various orthogonal analytical tools to study the protein's primary, secondary, and tertiary structure. The amino acid sequence for the disulfide-linked peptide was mapped using collision-induced dissociation (CID) to confirm the formation of interchain disulfide bonds between Cys7-Cys7 and Cys10-Cys10 similarly for intra-chain disulfide bonds between Cys42-Cys102, and Cys148-Cys206. The developed protocol here is a valuable tool to identify high-yield scalable refolding conditions for multi-domain proteins involving inter-domain disulfide bonds.
Collapse
Affiliation(s)
- Sunil Rana
- Chemical Engineering and Process Development Division, CSIR-National Chemical Laboratory, Pune 411008, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
| | - Santosh Ughade
- Chemical Engineering and Process Development Division, CSIR-National Chemical Laboratory, Pune 411008, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
| | - Rupali Kumthekar
- Chemical Engineering and Process Development Division, CSIR-National Chemical Laboratory, Pune 411008, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
| | - Rahul Bhambure
- Chemical Engineering and Process Development Division, CSIR-National Chemical Laboratory, Pune 411008, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
| |
Collapse
|
2
|
Østergaard S, Paulsson JF, Kofoed J, Zosel F, Olsen J, Jeppesen CB, Spetzler J, Ynddal L, Schleiss LG, Christoffersen BØ, Raun K, Sensfuss U, Nielsen FS, Jørgensen R, Wulff BS. The effect of fatty diacid acylation of human PYY 3-36 on Y 2 receptor potency and half-life in minipigs. Sci Rep 2021; 11:21179. [PMID: 34707178 PMCID: PMC8551270 DOI: 10.1038/s41598-021-00654-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Accepted: 10/13/2021] [Indexed: 01/02/2023] Open
Abstract
Peptides are notoriously known to display very short in vivo half-lives often measured in minutes which in many cases greatly reduces or eliminates sufficient in vivo efficacy. To obtain long half-lives allowing for up to once-weekly dosing regimen, fatty acid acylation (lipidation) have been used to non-covalently associate the peptide to serum albumin thus serving as a circulating depot. This approach is generally considered in the scientific and patent community as a standard approach to protract almost any given peptide. However, it is not trivial to prolong the half-life of peptides by lipidation and still maintain high potency and good formulation properties. Here we show that attaching a fatty acid to the obesity-drug relevant peptide PYY3-36 is not sufficient for long pharmacokinetics (PK), since the position in the backbone, but also type of fatty acid and linker strongly influences PK and potency. Furthermore, understanding the proteolytic stability of the backbone is key to obtain long half-lives by lipidation, since backbone cleavage still occurs while associated to albumin. Having identified a PYY analogue with a sufficient half-life, we show that in combination with a GLP-1 analogue, liraglutide, additional weight loss can be achieved in the obese minipig model.
Collapse
Affiliation(s)
- Søren Østergaard
- Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.
| | - Johan F Paulsson
- Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark
| | - Jacob Kofoed
- Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark
| | - Franziska Zosel
- Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark
| | - Jørgen Olsen
- Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark
| | - Claus Bekker Jeppesen
- Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark
| | - Jane Spetzler
- Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark
| | - Lars Ynddal
- Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.,Gubra Aps, Hørsholm Kongevej 11B, 2970, Hørsholm, Denmark
| | - Luise Gram Schleiss
- Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark
| | | | - Kirsten Raun
- Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark
| | - Ulrich Sensfuss
- Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.,STipe Therapeutics, Copenhagen, Denmark
| | - Flemming Seier Nielsen
- Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark
| | - Rasmus Jørgensen
- Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark.,CitoKi Pharma, Værløse, Denmark
| | - Birgitte S Wulff
- Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, 2760, Maaloev, Denmark
| |
Collapse
|
4
|
Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells. MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT 2015; 2:15043. [PMID: 26605373 PMCID: PMC4632835 DOI: 10.1038/mtm.2015.43] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/15/2015] [Revised: 09/05/2015] [Accepted: 09/29/2015] [Indexed: 12/14/2022]
Abstract
Antibody-dependent cellular cytotoxicity (ADCC), a key effector function for the clinical effectiveness of monoclonal antibodies, is triggered by the engagement of the antibody Fc domain with the Fcγ receptors expressed by innate immune cells such as natural killer (NK) cells and macrophages. Here, we fused cancer cell-binding peptides to the Fc domain of human IgG1 to engineer novel peptide-Fc fusion proteins with ADCC activity. The designed fusion proteins were expressed in human embryonic kidney 293T cells, followed by purification and characterization by western blots. One of the engineered variants (WN-Fc), bound with high affinity to a wide range of solid tumor cell lines (e.g., colon, lung, prostate, skin, ovarian, and mammary tumors). Treatment of cancer cells with the engineered peptide-Fc fusions in the presence of effector NK cells potentially enhanced cytotoxicity, degranulation, and interferon-γ production by NK cells when compared to cells treated with the Fc control. The presence of competing peptides inhibited NK cell activation. Furthermore, a bispecific peptide-Fc fusion protein activated NK cells against HER-1- and/or HER-2-expressing cancer cells. Collectively, the engineered peptide-Fc fusions constitute a new promising strategy to recruit and activate NK cells against tumor cells, a primary goal of cancer immunotherapy.
Collapse
|
5
|
Carlson K, Pomerantz SC, Vafa O, Naso M, Strohl W, Mains RE, Eipper BA. Optimizing production of Fc-amidated peptides by Chinese hamster ovary cells. BMC Biotechnol 2015; 15:95. [PMID: 26475607 PMCID: PMC4609047 DOI: 10.1186/s12896-015-0210-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2015] [Accepted: 10/01/2015] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Amidation of the carboxyl terminal of many peptides is essential for full biological potency, often increasing receptor binding and stability. The single enzyme responsible for this reaction is peptidylglycine α-amidating monooxygenase (PAM: EC 1.14.17.3), a copper- and ascorbate-dependent Type I membrane protein. METHODS To make large amounts of high molecular weight amidated product, Chinese hamster ovary (CHO) cells were engineered to express exogenous PAM. To vary access of the enzyme to its substrate, exogenous PAM was targeted to the endoplasmic reticulum, trans-Golgi network, endosomes and lysosomes or to the lumen of the secretory pathway. RESULTS PAM was equally active when targeted to each intracellular location and assayed in homogenates. Immunocytochemical analyses of CHO cells and a pituitary cell line demonstrated that targeting of exogenous PAM was partially successful. PAM substrates generated by expressing peptidylglycine substrates (glucagon-like peptide 1-Gly, peptide YY-Gly and neuromedin U-Gly) fused to the C-terminus of immunoglobulin Fc in CHO cell lines producing targeted PAM. The extent of amidation of the Fc-peptides was determined by mass spectrometry and amidation-specific enzyme immunoassays. Amidation was inhibited by copper chelation, but was not enhanced by the addition of additional copper or ascorbate. CONCLUSIONS Peptide amidation was increased over endogenous levels by exogenous PAM, and targeting PAM to the endoplasmic reticulum or trans-Golgi network increased peptide amidation compared to endogenous CHO PAM.
Collapse
Affiliation(s)
- Kristina Carlson
- Department of Neuroscience, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, 06030-3401, USA.
| | - Steven C Pomerantz
- Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
| | - Omid Vafa
- Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
| | - Michael Naso
- Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
| | - William Strohl
- Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
| | - Richard E Mains
- Department of Neuroscience, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, 06030-3401, USA.
| | - Betty A Eipper
- Department of Neuroscience, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, 06030-3401, USA. .,Department of Molecular Biology and Biophysics, University of Connecticut Health Center, Farmington, CT, 06030, USA.
| |
Collapse
|